Ibrutinib Delays Need for Next Treatment in Real-World First-Line CLL
A new, real-world study using more than 2 years of EMRs shows that patients with chronic...
Read More
Meeting Coverage
Test Your SOHO Knowledge!
A quiz based on the latest lung cancer news and studies from SOHO.
Read More
Test Your ASN Knowledge!
The ASN 2022 PhysQuiz was created by the editorial staff at Physician’s...
Read More
Metabolic Tumor Volume Predicts Response to Loncastuximab Tesirine in DLBCL
Metabolic tumor volume (MTV) was reported at the 2022 annual meeting of the American Society of...
Read More
Blinatumomab Candidate for Standard-of-Care in Newly Diagnosed B-ALL
measurable residual disease (MRD)-negative showed an overall survival (OS) benefit if they were...
Read More
Novel Therapy May Replace Standard-of-Care Prophylaxis for GVHD
Post-transplant cyclophosphamide/tacrolimus/mycophenolate mofetil outperformed...
Read More
Odronextamab Scores in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Odronextamab, an investigational bi-specific antibody targeting CD20 and CD3, showed promising...
Read More
High-Dose Chemotherapy Plus ASCT Superior to Standard Immune-Chemotherapy in Primary CNS Lymphoma
Consolidation high-dose chemotherapy followed by autologous stem cell transplantation (HCT/ASCT)...
Read More
Intensive Chemotherapy Prior to Allo-HCT in Rel/Ref AML?
Intensive chemotherapy, in advance of allogeneic hematopoietic cell transplantation (allo-HCT),...
Read More
Ibrutinib Plus Venetoclax Displays Long-Term Benefits in CLL
The 5-year follow-up data of the CAPTIVATE study demonstrated that first-line ibrutinib plus...
Read More
Ibrutinib Added to ASCT Improves Clinical Outcomes in Mantle Cell Lymphoma
In patients with previously untreated mantle cell lymphoma (MCL), autologous stem cell...
Read More
High-Dose Methotrexate or Standard Interim Maintenance in Young Patients with ALL?
High-dose methotrexate was not associated with a reduction in the risk for CNS relapse compared...
Read More
Promising Results for Triplet Therapy With Magrolimab in AML
Triplet therapy of azacitidine, venetoclax, and magrolimab was safe as first-line therapy in...
Read More
AHA 2022 eBook
A curated ebook of recent studies, findings, and thought leader perspectives from AHA 2022.
Read More
Test Your ECTRIMS on NMOSD Knowledge!
A quiz based on the latest NMOSD news and research from ECTRIMS.
Read More
ASN 2022 eBook
Focus on ASN Chronic Gout 2022.indd
Read More
Quality of Gout Care Suboptimal Among Aged Care Residents
Almost one-third of residents with gout living in aged care facilities did not receive...
Read More